SOMERSET, N.J., June 11, 2025 — Spring Bio Solution, a leading global provider of comparator sourcing, has introduced NCE Grid, a complimentary tool designed to streamline and visualize opportunities related to Para IV filings and NCE-1 exclusivity in real-time.

Previously, monitoring NCE exclusivity and Para IV filings involved a complex, manual process with information scattered across multiple sources. Regulatory updates were found on various platforms, key data was isolated in different databases, and timelines were managed using spreadsheets. This resulted in a lack of clear insights, uncoordinated R&D efforts, and missed opportunities.

For generic drug companies aiming for first-to-file status, incomplete information, dispersed data, and missed deadlines could lead to lost exclusivity and significant revenue losses.

NCE Grid addresses these challenges.

NCE Grid is a free platform that consolidates essential data points, including molecule details, innovator name, NCE-1 date, revenue, therapeutic use, projected sales growth, and CAGR%, into a single, user-friendly interface. Through real-time visualizations and actionable insights, NCE Grid enables strategy, regulatory, and portfolio teams to quickly identify, prioritize, and capitalize on first-to-file opportunities.

“We developed NCE Grid to help companies overcome the challenges of fragmented insights and missed opportunities,” stated Salim Shaikh, Founder and CEO of Spring Bio Solution. “In a market where timing is critical, our platform offers clarity, speed, and a competitive advantage to decision-makers. Think of NCE Grid as your go-to resource for Para IV and strategic drug development.”

To learn more, visit

About Spring Bio Solution

Spring Bio Solution collaborates with CROs, pharmaceutical firms, and research institutions globally, delivering reliable solutions for comparator sourcing and clinical trial supplies. With facilities holding wholesale drug distribution licenses (WDL) in the USA, EU, Singapore, and India, and a network of over 400 distribution partners and 30 innovators, Spring Bio Solution ensures prompt and compliant access to vital drug supplies.

Trusted by over 600 clients, and achieving a 99.9% success rate in sourcing comparator drugs, RLDs, and innovator samples, the company provides advanced cold chain management capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also guarantees complete DSCSA compliance and comprehensive traceability.

With experience in supporting more than 1,000 clinical trials and 12,000+ bioequivalence studies, Spring Bio Solution empowers sponsors to reduce operational risks and accelerate drug development with confidence.

For media inquiries, please contact:

Navdeep Trivedi
Vice President & Head, Digital Marketing

“`